8/104 sources · 4 publishersUpdated Oct 8, 18:07 UTC
Armenia grants first approvals for Agenus colorectal cancer drug pair
Armenia’s Health Ministry authorized Agenus’ Botvymo and Evamplix for combined use in adults with previously treated microsatellite-stable metastatic colorectal cancer who do not have active liver metastases. The approvals took effect October 2, 2026 and are the medicines’ first marketing clearances worldwide. Each authorization lasts one year and can be renewed following annual clinical updates to Armenia’s regulator.
Why it matters
The decision creates the first commercial authorization for the Botvymo-Evamplix regimen. Agenus says it will assess pursuing authorizations in other Eurasian Economic Union member states.
Key facts
- 1Armenia authorized Botvymo and Evamplix for combination treatment of eligible adults with microsatellite-stable metastatic colorectal cancer lacking active liver metastases after prior standard treatment. elliotlakestandard.ca
- 2The Armenian authorizations became effective on October 2, 2026. elliotlakestandard.ca
- 3The approvals are conditional, run for one year, and may be renewed using annual clinical information supplied by Agenus. elliotlakestandard.ca
- 4Botvymo’s approved schedule is 75 mg intravenously every 6 weeks for up to 4 doses. elliotlakestandard.ca
- 5Evamplix’s approved schedule is 240 mg by intravenous infusion every 2 weeks, for as long as 2 years unless the cancer advances or toxicity becomes unacceptable. elliotlakestandard.ca
- 6The authorizations drew on the Phase 1b C-800-01 study and randomized Phase 2 C-800-25 study. elliotlakestandard.ca
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.